Engineered BDNF producing cells as a potential treatment for neurologic disease
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Brain-derived neurotrophic factor (BDNF) has been implicated in wide range of neurological diseases and injury. This neurotrophic factor is vital for neuronal health, survival, and synaptic connectivity. Many therapies focus on the restoration or enhancement of BDNF following injury or disease progression. AREAS COVERED: The present review will focus on the mechanisms in which BDNF exerts its beneficial functioning, current BDNF therapies, issues and potential solutions for delivery of neurotrophic factors to the central nervous system, and other disease indications that may benefit from overexpression or restoration of BDNF. EXPERT OPINION: Due to the role of BDNF in neuronal development, maturation, and health, BDNF is implicated in numerous neurological diseases making it a prime therapeutic agent. Numerous studies have shown the therapeutic potential of BDNF in a number of neurodegenerative disease models and in acute CNS injury, however clinical translation has fallen short due to issues in delivering this molecule. The use of MSC as a delivery platform for BDNF holds great promise for clinical advancement of neurotrophic factor restoration. The ease with which MSC can be engineered opens the door to the possibility of using this cell-based delivery system to advance a BDNF therapy to the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Egan, M. F., Kojima, M., Callicott, J. H., Goldberg, T. E., Kolachana, B. S., Bertolino, A., Zaitsev, E., Gold, B., Goldman, D., Dean, M., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00035-7 · Cited by 3,888 · cited 1×
“[25] A mutation (val66met) in the proregion results in poorer sorting of BDNF into vesicles [26]”
BackgroundTrk Receptors: Roles in Neuronal Signal Transduction
Huang, E. J., & Reichardt, L. F. (2003) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161629 · Cited by 2,537 · cited 1×
“synaptic plasticity, and apoptosis.[14] This is achieved by three major signaling pathways: the phosphatidyl inositol 3-”
BackgroundNeurotrophin signal transduction in the nervous system
Kaplan, D. R., & Miller, F. D. (2000) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00092-1 · Cited by 1,944 · cited 1×
“various canonical signaling cascades [5] that influence survival,”
BackgroundPurification of a new neurotrophic factor from mammalian brain.
Barde, Y. A., Edgar, D., & Thoenen, H. (1982) · The EMBO Journal · doi:10.1002/j.1460-2075.1982.tb01207.x · Cited by 1,822 · cited 1×
“The first NTF, nerve growth factor (NGF), was discovered in the 1950s by a group of embryologists,[1] and over the past 50 years additional NTFs such as brain-derived neurotrophic factor (BDNF) in pig brain in 1982,[2] neurotrophin 3 (NT3),[3] and neurotrophin 4 (NT4) [4] have been discovered.”
BackgroundRegulation of Cell Survival by Secreted Proneurotrophins
Lee, R., Kermani, P., Teng, K. K., & Hempstead, B. L. (2001) · Science · doi:10.1126/science.1065057 · Cited by 1,670
Brain-Derived Neurotrophic Factor and Neuropsychiatric Disorders
Autry, A. E., & Monteggia, L. M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.005108 · Cited by 1,390 · cited 1×
“BDNF impairment has been related to a number of neurocognitive disorders (reviewed in [56]), particularly in anxiety [57,58] and may contribute to the cognitive and emotional disturbances observed in HD.”
BackgroundTransport of brain-derived neurotrophic factor across the blood–brain barrier
Pan, W., Banks, W. A., Fasold, M. B., Bluth, J., & Kastin, A. J. (1998) · Neuropharmacology · doi:10.1016/s0028-3908(98)00141-5 · Cited by 1,354
Long-Lasting Neurotrophin-Induced Enhancement of Synaptic Transmission in the Adult Hippocampus
Kang, H., & Schuman, E. M. (1995) · Science · doi:10.1126/science.7886457 · Cited by 1,354 · cited 1×
“Exogenous BDNF increases glutamate transmission in rodent brain slices of the hippocampus [42] and visual”
BackgroundNeurotrophin-3: a Neurotrophic Factor Related to NGF and BDNF
Maisonpierre, P. C., Belluscio, L., Squinto, S., Ip, N. Y., Furth, M. E., Lindsay, R. M., & Yancopoulos, G. D. (1990) · Science · doi:10.1126/science.2321006 · Cited by 1,322
BDNF function in adult synaptic plasticity: The synaptic consolidation hypothesis
Bramham, C. R., & Messaoudi, E. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.06.003 · Cited by 1,193
Cited by
Miranda, M., Morici, J. F., Zanoni, M. B., & Bekinschtein, P. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00363 · Cited by 1,416
Functional role of mesenchymal stem cells in the treatment of chronic neurodegenerative diseases
Lo Furno, D., Mannino, G., & Giuffrida, R. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26192 · Cited by 177
Rauti, R., Cellot, G., D’Andrea, P., Colliva, A., Scaini, D., Tongiorgi, E., & Ballerini, L. (2020) · Molecular Brain · doi:10.1186/s13041-020-00582-9 · Cited by 78
Metadata
- Authors
- Deng, P., Anderson, J. D., Yu, A. S., Annett, G., Fink, K. D., & Nolta, J. A.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa UK Limited
- Published
- 2016-05-21
- Volume
- 16
- Issue
- 8
- Pages
- 1025-1033
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W2345609685
- Cited by
- 67
- References
- 30
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Engineered BDNF producing cells as a potential treatment for neurologic disease. https://app.cochat.ai/papers/10.1080/14712598.2016.1183641
- The paper
- Deng, P., Anderson, J. D., Yu, A. S., Annett, G., Fink, K. D., & Nolta, J. A. (2016). Engineered BDNF producing cells as a potential treatment for neurologic disease. Expert Opinion on Biological Therapy. https://doi.org/10.1080/14712598.2016.1183641
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.